Skip to main content
Top
Published in: BMC Infectious Diseases 1/2020

01-12-2020 | Vulvovaginal Candidiasis | Research article

Molecular identification and antifungal susceptibility profile of yeast from vulvovaginal candidiasis

Authors: Yu Shi, Yuxia Zhu, Shangrong Fan, Xiaoping Liu, Yiheng Liang, Yingying Shan

Published in: BMC Infectious Diseases | Issue 1/2020

Login to get access

Abstract

Background

Accurate identification Candida is important for successful therapy and epidemiology study. The aim of research is to study API 20C yeast identification system identification rate by using molecular identification as gold standard and tested the antifungal susceptibility of Candida from patients with vulvovaginal candidiasis (VVC).

Methods

In total, 3574 yeast isolates were obtained from patients with VVC. API 20C yeast identification, molecular identification and in vitro antifungal susceptibility were performed.

Results

C. albicans was the predominant Candida species [2748 isolates, 76.9%] in VVC. The isolates from vaginal samples represented 22 species based on molecular identification. The API 20C system identifies only 11 of the species encountered during the study period. Based on the API 20C system, 3273 (91.58%) isolates were correctly identified to the species level. The correct identification rate of the API 20C system for rare yeast was 15.29% (26/170 isolates). Antifungal susceptibility was tested in a total of 1844 isolates of Candida from patients with VVC. C. albicans was susceptible to most of the tested antifungals. The MICs of azoles for C. glabrata were higher than those for C. albicans. The MICs of echinocandins for C. parapsilosis were higher than those for C. albicans.

Conclusions

The API 20C yeast identification system can be used to reliably identify the most common Candida species while molecular methods are necessary for the identification of closely related, emerging, and rare yeast species. The results from this study suggest that much of the previous studies on the epidemiology of VVC should be re-thought. C. albicans was susceptible to most of the tested antifungals.
Literature
1.
go back to reference Workowski KA, Bolan GA. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015;64(RR-03):1–137.PubMed Workowski KA, Bolan GA. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015;64(RR-03):1–137.PubMed
2.
go back to reference Blostein F, Levin-Sparenberg E, Wagner J, Foxman B. Recurrent vulvovaginal candidiasis. Ann Epidemiol. 2017;27(9):575–82 e3.CrossRefPubMed Blostein F, Levin-Sparenberg E, Wagner J, Foxman B. Recurrent vulvovaginal candidiasis. Ann Epidemiol. 2017;27(9):575–82 e3.CrossRefPubMed
3.
go back to reference Liu XP, Fan SR, Peng YT, Zhang HP. Species distribution and susceptibility of Candida isolates from patient with vulvovaginal candidiasis in southern China from 2003 to 2012. J Mycol Med. 2014;24(2):106–11.CrossRefPubMed Liu XP, Fan SR, Peng YT, Zhang HP. Species distribution and susceptibility of Candida isolates from patient with vulvovaginal candidiasis in southern China from 2003 to 2012. J Mycol Med. 2014;24(2):106–11.CrossRefPubMed
4.
go back to reference Wang FJ, Zhang D, Liu ZH, Wu WX, Bai HH, Dong HY. Species distribution and in vitro antifungal susceptibility of vulvovaginal Candida isolates in China. Chin Med J. 2016;129(10):1161–5.CrossRefPubMedPubMedCentral Wang FJ, Zhang D, Liu ZH, Wu WX, Bai HH, Dong HY. Species distribution and in vitro antifungal susceptibility of vulvovaginal Candida isolates in China. Chin Med J. 2016;129(10):1161–5.CrossRefPubMedPubMedCentral
5.
go back to reference Ng KP, Kuan CS, Kaur H, Na SL, Atiya N, Velayuthan RD. Candida species epidemiology 2000-2013: a laboratory-based report. Tropical Med Int Health. 2015;20(11):1447–53.CrossRef Ng KP, Kuan CS, Kaur H, Na SL, Atiya N, Velayuthan RD. Candida species epidemiology 2000-2013: a laboratory-based report. Tropical Med Int Health. 2015;20(11):1447–53.CrossRef
6.
go back to reference Gonçalves B, Ferreira C, Alves CT, Henriques M, Azeredo J, Silva S. Vulvovaginal candidiasis: epidemiology, microbiology and risk factors. Crit Rev Microbiol. 2016;42(6):905–27.CrossRefPubMed Gonçalves B, Ferreira C, Alves CT, Henriques M, Azeredo J, Silva S. Vulvovaginal candidiasis: epidemiology, microbiology and risk factors. Crit Rev Microbiol. 2016;42(6):905–27.CrossRefPubMed
7.
go back to reference Posteraro B, Efremov L, Leoncini E, Amore R, Posteraro P, Ricciardi W, Sanguinetti M. Are the conventional commercial yeast identification methods still helpful in the era of new clinical microbiology diagnostics? A meta-analysis of their accuracy. J Clin Microbiol. 2015;53(8):2439–50.CrossRefPubMedPubMedCentral Posteraro B, Efremov L, Leoncini E, Amore R, Posteraro P, Ricciardi W, Sanguinetti M. Are the conventional commercial yeast identification methods still helpful in the era of new clinical microbiology diagnostics? A meta-analysis of their accuracy. J Clin Microbiol. 2015;53(8):2439–50.CrossRefPubMedPubMedCentral
8.
go back to reference Criseo G, Scordino F, Romeo O. Current methods for identifying clinically important cryptic Candida species. J Microbiol Methods. 2015;111:50–6.CrossRefPubMed Criseo G, Scordino F, Romeo O. Current methods for identifying clinically important cryptic Candida species. J Microbiol Methods. 2015;111:50–6.CrossRefPubMed
9.
go back to reference Sobel JDand Akins RA. The role of PCR in the diagnosis of Candida vulvovaginitis-a new gold standard? Curr Infect Dis Rep. 2015;17(6):488.PubMed Sobel JDand Akins RA. The role of PCR in the diagnosis of Candida vulvovaginitis-a new gold standard? Curr Infect Dis Rep. 2015;17(6):488.PubMed
10.
go back to reference Sobel JDand Sobel R. Current treatment options for vulvovaginal candidiasis caused by azole-resistant Candida species. Expert Opin Pharmacother. 2018;19(9):971–7.CrossRefPubMed Sobel JDand Sobel R. Current treatment options for vulvovaginal candidiasis caused by azole-resistant Candida species. Expert Opin Pharmacother. 2018;19(9):971–7.CrossRefPubMed
11.
go back to reference Denning DW, Kneale M, Sobel JD, Rautemaa-Richardson R. Global burden of recurrent vulvovaginal candidiasis: a systematic review. Lancet Infect Dis. 2018;18(11):e339–47.CrossRefPubMed Denning DW, Kneale M, Sobel JD, Rautemaa-Richardson R. Global burden of recurrent vulvovaginal candidiasis: a systematic review. Lancet Infect Dis. 2018;18(11):e339–47.CrossRefPubMed
12.
go back to reference Brand SR, Degenhardt TP, Person K, Sobel JD, Nyirjesy P, Schotzinger RJ, Tavakkol A. A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of orally administered VT-1161 in the treatment of recurrent vulvovaginal candidiasis. Am J Obstet Gynecol. 2018;218(6):624.e1–9.CrossRef Brand SR, Degenhardt TP, Person K, Sobel JD, Nyirjesy P, Schotzinger RJ, Tavakkol A. A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of orally administered VT-1161 in the treatment of recurrent vulvovaginal candidiasis. Am J Obstet Gynecol. 2018;218(6):624.e1–9.CrossRef
13.
go back to reference Garvey EP, Hoekstra WJ, Schotzinger RJ, Sobel JD, Lilly EA, Fidel PL Jr. Efficacy of the clinical agent VT-1161 against fluconazole-sensitive and -resistant Candida albicans in a murine model of vaginal candidiasis. Antimicrob Agents Chemother. 2015;59(9):5567–73.CrossRefPubMedPubMedCentral Garvey EP, Hoekstra WJ, Schotzinger RJ, Sobel JD, Lilly EA, Fidel PL Jr. Efficacy of the clinical agent VT-1161 against fluconazole-sensitive and -resistant Candida albicans in a murine model of vaginal candidiasis. Antimicrob Agents Chemother. 2015;59(9):5567–73.CrossRefPubMedPubMedCentral
14.
go back to reference Boikov DA, Locke JB, James KD, Bartizal K, Sobel JD. In vitro activity of the novel echinocandin CD101 at pH 7 and 4 against Candida spp. isolates from patients with vulvovaginal candidiasis. J Antimicrob Chemother. 2017;72(5):1355–8.CrossRefPubMedPubMedCentral Boikov DA, Locke JB, James KD, Bartizal K, Sobel JD. In vitro activity of the novel echinocandin CD101 at pH 7 and 4 against Candida spp. isolates from patients with vulvovaginal candidiasis. J Antimicrob Chemother. 2017;72(5):1355–8.CrossRefPubMedPubMedCentral
15.
go back to reference Nyirjesy P, Alessio C, Jandourek A, Lee JD, Sandison T. Sobel JD.CD101 topical compared with oral fluconazole for acute vulvovaginal candidiasis: a randomized controlled trial. J Low Genit Tract Dis. 2019;23(3):226–9.CrossRefPubMed Nyirjesy P, Alessio C, Jandourek A, Lee JD, Sandison T. Sobel JD.CD101 topical compared with oral fluconazole for acute vulvovaginal candidiasis: a randomized controlled trial. J Low Genit Tract Dis. 2019;23(3):226–9.CrossRefPubMed
16.
go back to reference Shan Y, Fan S, Liu X, Li J. Prevalence of Candida albicans-closely related yeasts, Candida africana and Candida dubliniensis, in vulvovaginal candidiasis. Med Mycol. 2014;52(6):636–40.CrossRefPubMed Shan Y, Fan S, Liu X, Li J. Prevalence of Candida albicans-closely related yeasts, Candida africana and Candida dubliniensis, in vulvovaginal candidiasis. Med Mycol. 2014;52(6):636–40.CrossRefPubMed
17.
go back to reference Li J, Shan Y, Fan S, Liu X. Prevalence of Candida nivariensis and Candida bracarensis in vulvovaginal candidiasis. Mycopathologia. 2014;178(3–4):279–83.CrossRefPubMed Li J, Shan Y, Fan S, Liu X. Prevalence of Candida nivariensis and Candida bracarensis in vulvovaginal candidiasis. Mycopathologia. 2014;178(3–4):279–83.CrossRefPubMed
18.
go back to reference Asadzadeh M, Ahmad S, Hagen F, Meis JF, Al-Sweih N, Khan Z. Simple, low-cost detection of Candida parapsilosis complex isolates and molecular fingerprinting of Candida orthopsilosis strains in Kuwait by ITS region sequencing and amplified fragment length polymorphism analysis. PLoS One. 2015;10(11):e0142880.CrossRefPubMedPubMedCentral Asadzadeh M, Ahmad S, Hagen F, Meis JF, Al-Sweih N, Khan Z. Simple, low-cost detection of Candida parapsilosis complex isolates and molecular fingerprinting of Candida orthopsilosis strains in Kuwait by ITS region sequencing and amplified fragment length polymorphism analysis. PLoS One. 2015;10(11):e0142880.CrossRefPubMedPubMedCentral
19.
go back to reference Leaw SN, Chang HC, Sun HF, Barton R, Bouchara JP, Chang TC. Identification of medically important yeast species by sequence analysis of the internal transcribed spacer regions. J Clin Microb. 2006;44(3):693–9.CrossRef Leaw SN, Chang HC, Sun HF, Barton R, Bouchara JP, Chang TC. Identification of medically important yeast species by sequence analysis of the internal transcribed spacer regions. J Clin Microb. 2006;44(3):693–9.CrossRef
20.
go back to reference CLSI. Reference method for broth dilution antifungal susceptibility testing of yeasts; third edition; CLSI document M27-A3. Wayne: Clinical and Laboratory Standards Institute; 2008. CLSI. Reference method for broth dilution antifungal susceptibility testing of yeasts; third edition; CLSI document M27-A3. Wayne: Clinical and Laboratory Standards Institute; 2008.
21.
go back to reference CLSI. Reference method for broth dilution antifungal susceptibility testing of yeasts; 1st ed, M60. Wayne: Clinical and Laboratory Standards Institute; 2017. CLSI. Reference method for broth dilution antifungal susceptibility testing of yeasts; 1st ed, M60. Wayne: Clinical and Laboratory Standards Institute; 2017.
22.
go back to reference Borman AM, Szekely A, Palmer MD, Johnson EM. Assessment of accuracy of identification of pathogenic yeasts in microbiology laboratories in the United Kingdom. J Clin Microbiol. 2012;50(8):2639–44.CrossRefPubMedPubMedCentral Borman AM, Szekely A, Palmer MD, Johnson EM. Assessment of accuracy of identification of pathogenic yeasts in microbiology laboratories in the United Kingdom. J Clin Microbiol. 2012;50(8):2639–44.CrossRefPubMedPubMedCentral
23.
go back to reference Durán-Valle MT, Sanz-Rodríguez N, Muñoz-Paraíso C, Almagro-Moltó M, Gómez-Garcés JL. Identification of clinical yeasts by Vitek MS system compared with API ID 32 C. Med Mycol. 2014;52(4):342–9.CrossRefPubMed Durán-Valle MT, Sanz-Rodríguez N, Muñoz-Paraíso C, Almagro-Moltó M, Gómez-Garcés JL. Identification of clinical yeasts by Vitek MS system compared with API ID 32 C. Med Mycol. 2014;52(4):342–9.CrossRefPubMed
24.
go back to reference Gündeş SG, Gulenc S, Bingol R. Comparative performance of Fungichrom I, Candifast and API 20C aux systems in the identification of clinically significant yeasts. J Med Microbiol. 2002;50(12):1105–10.CrossRef Gündeş SG, Gulenc S, Bingol R. Comparative performance of Fungichrom I, Candifast and API 20C aux systems in the identification of clinically significant yeasts. J Med Microbiol. 2002;50(12):1105–10.CrossRef
25.
go back to reference Arastehfar A, Daneshnia F, Kord M, Roudbary M, Zarrinfar H, Fang W, Najafzadeh MJ, Khodavaisy S, Pan W, Liao W, Badali H, Rezaie S, Zomorodian K, Hagen F, Boekhout T. Comparison of 21-plex PCR and API 20C AUX, MALDI-TOF MS, and rDNA sequencing for a wide range of clinically isolated yeast species: improved identification by combining 21-plex PCR and API 20C AUX as an alternative strategy for developing countries. Front Cell Infect Microbiol. 2019;9:21. Arastehfar A, Daneshnia F, Kord M, Roudbary M, Zarrinfar H, Fang W, Najafzadeh MJ, Khodavaisy S, Pan W, Liao W, Badali H, Rezaie S, Zomorodian K, Hagen F, Boekhout T. Comparison of 21-plex PCR and API 20C AUX, MALDI-TOF MS, and rDNA sequencing for a wide range of clinically isolated yeast species: improved identification by combining 21-plex PCR and API 20C AUX as an alternative strategy for developing countries. Front Cell Infect Microbiol. 2019;9:21.
26.
go back to reference Zhu Y, Shan Y, Fan S, Li J, Liu X. Candida parapsilosis sensu stricto and the closely related species Candida orthopsilosis and Candida metapsilosis in vulvovaginal candidiasis. Mycopathologia. 2015;179(1–2):111–8.CrossRefPubMed Zhu Y, Shan Y, Fan S, Li J, Liu X. Candida parapsilosis sensu stricto and the closely related species Candida orthopsilosis and Candida metapsilosis in vulvovaginal candidiasis. Mycopathologia. 2015;179(1–2):111–8.CrossRefPubMed
27.
go back to reference Kalkanci A, Güzel AB, Khalil II, Aydin M, Ilkit M, Kuştimur S. Yeast vaginitis during pregnancy: susceptibility testing of 13 antifungal drugs and boric acid and the detection of four virulence factors. Med Mycol. 2012;50(6):585–93.CrossRefPubMed Kalkanci A, Güzel AB, Khalil II, Aydin M, Ilkit M, Kuştimur S. Yeast vaginitis during pregnancy: susceptibility testing of 13 antifungal drugs and boric acid and the detection of four virulence factors. Med Mycol. 2012;50(6):585–93.CrossRefPubMed
28.
go back to reference Makanjuola O, Bongomin F, Fayemiwo SA. An update on the roles of non-albicans candida species in vulvovaginitis. J Fungi (Basel). 2018;4(4):121.CrossRef Makanjuola O, Bongomin F, Fayemiwo SA. An update on the roles of non-albicans candida species in vulvovaginitis. J Fungi (Basel). 2018;4(4):121.CrossRef
29.
go back to reference Xiao M, Fan X, Chen SC, Wang H, Sun ZY, Liao K, Chen SL, Yan Y, Kang M, Hu ZD, Chu YZ, Hu TS, Ni YX, Zou GL, Kong F, Xu YC. Antifungal susceptibilities of Candida glabrata species complex, Candida krusei, Candida parapsilosis species complex and Candida tropicalis causing invasive candidiasis in China: 3 year national surveillance. J Antimicrob Chemother. 2015;70(3):802–10.CrossRefPubMed Xiao M, Fan X, Chen SC, Wang H, Sun ZY, Liao K, Chen SL, Yan Y, Kang M, Hu ZD, Chu YZ, Hu TS, Ni YX, Zou GL, Kong F, Xu YC. Antifungal susceptibilities of Candida glabrata species complex, Candida krusei, Candida parapsilosis species complex and Candida tropicalis causing invasive candidiasis in China: 3 year national surveillance. J Antimicrob Chemother. 2015;70(3):802–10.CrossRefPubMed
30.
go back to reference Zhang L, Zhou S, Pan A, Li J, Liu B. Surveillance of antifungal susceptibilities in clinical isolates of Candida species at 36 hospitals in China from 2009 to 2013. Int J Infect Dis. 2015;33:1–4.CrossRefPubMed Zhang L, Zhou S, Pan A, Li J, Liu B. Surveillance of antifungal susceptibilities in clinical isolates of Candida species at 36 hospitals in China from 2009 to 2013. Int J Infect Dis. 2015;33:1–4.CrossRefPubMed
31.
go back to reference Delarze Eand Sanglard D. Defining the frontiers between antifungal resistance, tolerance and the concept of persistence. Drug Resist Updat. 2015;23:12–9.CrossRef Delarze Eand Sanglard D. Defining the frontiers between antifungal resistance, tolerance and the concept of persistence. Drug Resist Updat. 2015;23:12–9.CrossRef
32.
go back to reference Castanheira M, Deshpande LM, Davis AP, Rhomberg PR, Pfaller MA. Monitoring antifungal resistance in a global collection of invasive yeasts and molds: application of CLSI epidemiological cutoff values and whole-genome sequencing analysis for detection of azole resistance in Candida albicans. Antimicrob Agents Chemother. 2017;61(10):e00906–17. Castanheira M, Deshpande LM, Davis AP, Rhomberg PR, Pfaller MA. Monitoring antifungal resistance in a global collection of invasive yeasts and molds: application of CLSI epidemiological cutoff values and whole-genome sequencing analysis for detection of azole resistance in Candida albicans. Antimicrob Agents Chemother. 2017;61(10):e00906–17.
33.
go back to reference Nagashima M, Yamagishi Y, Mikamo H. Antifungal susceptibilities of Candida species isolated from the patients with vaginal candidiasis. J Infect Chemother. 2016;22(2):124–6.CrossRefPubMed Nagashima M, Yamagishi Y, Mikamo H. Antifungal susceptibilities of Candida species isolated from the patients with vaginal candidiasis. J Infect Chemother. 2016;22(2):124–6.CrossRefPubMed
34.
go back to reference Marchaim D, Lemanek L, Bheemreddy S, Kaye KS, Sobel JD. Fluconazole-resistant Candida albicans vulvovaginitis. Obstet Gynecol. 2012;120(6):1407–14.CrossRefPubMed Marchaim D, Lemanek L, Bheemreddy S, Kaye KS, Sobel JD. Fluconazole-resistant Candida albicans vulvovaginitis. Obstet Gynecol. 2012;120(6):1407–14.CrossRefPubMed
35.
go back to reference Bailly S, Maubon D, Fournier P, Pelloux H, Schwebel C, Chapuis C, Foroni L, Cornet M, Timsit JF. Impact of antifungal prescription on relative distribution and susceptibility of Candida spp. - trends over 10 years. J Inf Secur. 2016;72(1):103–11. Bailly S, Maubon D, Fournier P, Pelloux H, Schwebel C, Chapuis C, Foroni L, Cornet M, Timsit JF. Impact of antifungal prescription on relative distribution and susceptibility of Candida spp. - trends over 10 years. J Inf Secur. 2016;72(1):103–11.
36.
go back to reference Bulik CC, Sobel JD, Nailor MD. Susceptibility profile of vaginal isolates of Candida albicans prior to and following fluconazole introduction - impact of two decades. Mycoses. 2011;54(1):34–8.CrossRefPubMed Bulik CC, Sobel JD, Nailor MD. Susceptibility profile of vaginal isolates of Candida albicans prior to and following fluconazole introduction - impact of two decades. Mycoses. 2011;54(1):34–8.CrossRefPubMed
37.
go back to reference Fornari G, Vicente VA, Gomes RR, Muro MD, Pinheiro RL, Ferrari C, Herkert PF, Takimura M, Carvalho NS, Queiroz-Telles F. Susceptibility and molecular characterization of Candida species from patients with vulvovaginitis. Braz J Microbiol. 2016;47(2):373–80..CrossRefPubMedPubMedCentral Fornari G, Vicente VA, Gomes RR, Muro MD, Pinheiro RL, Ferrari C, Herkert PF, Takimura M, Carvalho NS, Queiroz-Telles F. Susceptibility and molecular characterization of Candida species from patients with vulvovaginitis. Braz J Microbiol. 2016;47(2):373–80..CrossRefPubMedPubMedCentral
38.
go back to reference Shi XY, Yang YP, Zhang Y, Li W, Wang JD, Huang WM, Fan YM. Molecular identification and antifungal susceptibility of 186 Candida isolates from vulvovaginalcandidiasis in southern China. J Med Microbiol. 2015;64(Pt 4):390–3.CrossRefPubMed Shi XY, Yang YP, Zhang Y, Li W, Wang JD, Huang WM, Fan YM. Molecular identification and antifungal susceptibility of 186 Candida isolates from vulvovaginalcandidiasis in southern China. J Med Microbiol. 2015;64(Pt 4):390–3.CrossRefPubMed
39.
go back to reference Ferahbas A, Koc AN, Uksal U, Aygen E, Mistik S, Yildiz S. Terbinafine versus itraconazole and fluconazole in the treatment of vulvovaginal candidiasis. Am J Ther. 2006;13(4):332–6.CrossRefPubMed Ferahbas A, Koc AN, Uksal U, Aygen E, Mistik S, Yildiz S. Terbinafine versus itraconazole and fluconazole in the treatment of vulvovaginal candidiasis. Am J Ther. 2006;13(4):332–6.CrossRefPubMed
Metadata
Title
Molecular identification and antifungal susceptibility profile of yeast from vulvovaginal candidiasis
Authors
Yu Shi
Yuxia Zhu
Shangrong Fan
Xiaoping Liu
Yiheng Liang
Yingying Shan
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2020
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-020-04985-w

Other articles of this Issue 1/2020

BMC Infectious Diseases 1/2020 Go to the issue